《中国血脂管理指南(2023年)》药物更新透视

Pharmacologic Therapy Updates of Chinese Guidelines for Lipid Management(2023)

血脂管理对于动脉粥样硬化性心血管疾病(ASCVD)的防治与预后改善十分重要。为更好地指导临床实践,《中国血脂管理指南(2023年)》在《中国成人血脂异常防治指南(2016年修订版)》基础上,结合国内外新的循证医学证据和中国国情,对从儿童到老年全生命周期的血脂管理,包括血脂检测项目、筛查频率、ASCVD风险评估及特定人群降脂目标、治疗原则、药物治疗方案等多个方面的内容进行了调整、扩增和完善。该文就治疗药物部分的更新进行综述。

Lipid management is very important for preventing and treating atherosclerotic cardiovascular disease(ASCVD)and improving prognosis.To better guide clinical practice,the Chinese Guidelines for Lipid Management(2023),which is based on the Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults(2016 Revision)with new evidence and clinical status both in China and abroad,provides guidance on lipid management throughout the life cycle from childhood to old age,including adjusting,expanding and improving lipid testing items,lipid screening frequency,ASCVD risk assessment,lipid-lowering targets for specific populations,treatment principles and drug treatment plans.This study is to review the updates of pharmacologic therapy in the guideline.